Charles River Laboratories, a contract research organization (CRO) with headquarters in Wilmington, Mass., is buying MPI Research for about $800 million.
Allergan Plc reported better-than-expected fourth-quarter 2017 profit and announced positive data on one of the two migraine treatments it is developing.
Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.
A federal judge sentenced Aegerion for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the victims.
Rare disease giant Shire plc purchased a preclinical autoimmune drug candidate being developed by AB Biosciences.
One week after Sanofi agreed to buy Waltham, Mass.-based Bioverativ for $11.6 billion, the French drugmaker announced the acquisition of Ghent, Belgium-based Ablynx for about $4.85 billion.
Johnson & Johnson said it would take a $13.6 billion charge related to the new U.S. tax law and plans to bring back billions of dollars from overseas immediately.
Biotech deal activity exploded with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products to their medicine cabinets.
Nuvo Pharmaceuticals acquired the U.S. rights to Resultz head lice treatment from Piedmont Pharmaceuticals.
Teva Pharmaceutical Industries’ board of directors agreed to take a 50 percent pay cut.